Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 633 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Stage IIIB Non-Small Cell Lung Cancer Clear all

Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Paclitaxel, Carboplatin, STA 4783; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Pomona, California • San Francisco, California + 15 more

Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions: Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Newport Beach, California

Conditions: Non-small Cell Lung Cancer
Interventions: capmatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • Fairfax, Virginia

Conditions: Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions: Nicotine Replacement Patch; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Cancer
Interventions: cisplatin, vinblastine sulfate, phosphorus P32, radiation therapy; Drug · Radiation
Lead sponsor: Center for Molecular Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Lung Cancer
Interventions: celecoxib, erlotinib hydrochloride; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Interventions: Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Chicago, Illinois + 4 more

Conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions: Avelumab, Axitinib, Palbociclib; Drug
Lead sponsor: Worldwide Innovative Network Association; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: La Jolla, California • Sioux Falls, South Dakota

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, celecoxib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Lung Cancer
Interventions: bevacizumab, pemetrexed disodium; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 248
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more

Conditions: Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions: cisplatin, fluoxetine, gemcitabine hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 42
States / cities: Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, tipifarnib, radiation therapy; Drug · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Bevacizumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, pemetrexed disodium; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 217
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 140 more

Conditions: Lung Cancer
Interventions: docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Las Vegas, Nevada + 4 more

Conditions: Lung Cancer
Interventions: vinorelbine tartrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 46
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 38 more

Conditions: Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions: SS1(dsFv)-PE38 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non Small Cell Lung Cancer
Interventions: Paclitaxel, NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab; Other · Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Lake Forest, Illinois

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 57
States / cities: Loma Linda, California • Pomona, California • New London, Connecticut + 46 more

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carboxyamidotriazole, paclitaxel; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: aminocamptothecin colloidal dispersion; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Survival Prolongation by Rationale Innovative Genomics

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Trial of Poor Performance Status Patients (ToPPS)

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer